Posted on July 23, 2012 by LaBovick Law

Convertino Privacy Act Case Reinstated: A Major Blow to the War on Whistleblowers

In Washington, D.C., on June 22, 2012, the Privacy Act case of former U.S. prosecutor Richard Convertino was reinstated by the U.S. Court of Appeals for the District of Columbia. This Privacy Act case accused the Bush Administration of deliberately leaking illegal information that was used to attack and tarnish the reputation of Mr. Convertino. The Court of Appeals’ decision now allows Richard Convertino to continue his research in order to figure out which current and/or former Justice Department employees went against the Privacy Act and attacked Mr. Convertino.

Richard Convertino blew the whistle on former Attorney General Ashcroft due to his poor handling of terrorist prosecutions in 2003. Despite being a former award-winning prosecutor who led many terrorism cases at the Department of Justice, Department of Justice officials sought revenge and leaked untrue and damaging information about Mr. Convertino to The Detroit Free Press. Mr. Convertino subsequently made a Privacy Act complaint in an attempt to oust the individual(s) who leaked the false information about him. 

Stephen M. Kohn, Executive Director of the National Whistleblowers Center, spoke about Richard Convertino’s case:

“The Justice Department’s policy of criminally investigating whistleblowers who ‘leak’ information, while at the same time aggressively defending its own ‘leakers,’ is hypocritical. In Mr. Convertino’s case, the Justice Department intentionally leaked information to destroy the reputation of the distinguished prosecutor who had the courage to challenge the Attorney General’s conduct in the ‘War on Terror.’ Moreover, the Justice Department has, for years, aggressively stood in the way of Mr. Convertino’s attempts to discover which official(s) retaliated against him.”

This case reversal is seen as a significant blow to the U.S. Department of Justice’s “War on Whistleblowers” and will hopefully result in reform regarding the double standard in the treatment of government “leakers.”

Tags: , , , , , , , , , , ,
Posted on May 8, 2012 by LaBovick Law

Politics is the only thing that will save the drug companies from their own illegal schemes

Florida Qui Tam

Politics is the only thing that will save the drug companies from their own illegal schemes. Unless they can gather the forces of the pro-business political wing of America, and change the law, I believe the Federal False Claims Act is working literal magic on the US budget by actually prosecuting drug companies for their illegal marketing of drugs for off-label use.

Today, the Department of Justice Announced a staggering $1,600,000,000 settlement with Abbott Labs. According to the Chicago Tribune (http://www.chicagotribune.com/business/breaking/chi-abbott-to-pay-16b-to-settle-depakote-claims-20120507,0,7263674.story), of the total award, $800,000,000 will resolve the civil case and $700,000,000 will resolve the criminal penalties and $100,000,000 will resolve the state consumer protection actions, which sprung out of the investigation.

How much money did Abbott Lab make to be able to buy themselves out of criminal and civil penalties? What was the giant settlement about? It was about Abbott Labs being accused of illegal marketing practices for its blockbuster drug Depakote. Depakote is an anti-seizure medication, and this settlement has generated a lot of negative press for Abbott. Recently ABC World News reported that the drug was being illegally prescribed in nursing homes nationwide. Abbott was allegedly convincing the nursing homes to use the drugs to treat aggression in dementia patients. In fact, they admitted they trained a special marketing force to teach the nursing homes that the drug was not regulated by the federal laws designed to stop the use of medications for unnecessary purposes in nursing homes. They did this even though they had no credible evidence or testing to show Depakote helped the condition.

There is a definite increase in the Justice Department's desire to prosecute illegal marketing schemes in which drug companies engage. This is especially true when the drug company markets their drug for an "off-label" use. Due to the number of calls we are now receiving to investigate this type of practice, it is almost worth specializing in just off-label drug cases as a law firm. Even in the Abbott settlement the Wall Street Journal is saying Abbott will still plead guilty to some criminal charges as well as to stay on probation for five years, during which time it must self report any probable violations of the law to their probation officer. That is amazing! To pay a staggering fine and then plead guilty to a crime is a harsh penalty.

According to the Washington Post (http://www.washingtonpost.com/national/health-science/abbott-laboratories-agrees-to-16-billion-settlement-over-marketing-of-depakote/2012/05/07/gIQAh5098T_story.html) this settlement is the "second-largest" enforcement action that is the result of the increased enforcement efforts by the Justice Department criminal division concentrating on drug makers off-label or misbranding their drugs in the market.

If you have a question regarding the marketing practices of any drug company, please call the LaBovick Law Group. We have staff trained to understand this type of claim and answer your questions.

Tags: , , , , , , , , , , , , , , , , ,